Table 1 Characteristics of the patient groups with and without apnea episodes (n = 121)
Variable | With apnea episodes (n = 59) | Without apnea episodes (n = 62) | P value |
|---|---|---|---|
Age (years), median (range) | 71 (23–82) | 69 (37–81) | 0.781 |
Gender (male), n (%) | 40 (67.8) | 42 (67.7) | 0.995 |
BMI (kg/m2), mean ± SD | 22.3 ± 2.8 | 21.3 ± 2.9 | 0.061 |
ASA physical status (I/II/III/IV), n | 15/36/8/0 | 25/31/6/0 | 0.214 |
Comorbidities and diagnoses, n (%) | |||
COPD | 1 (1.7) | 4 (6.5) | 0.365 |
ILD | 11 (18.6) | 8 (12.9) | 0.458 |
Infectious disease | 3 (5.1) | 3 (4.8) | 1.000 |
Malignancy | 41 (69.5) | 39 (62.9) | 0.565 |
Others | 12 (20.3) | 11 (17.7) | 0.818 |
Procedures, (%) | |||
Endobronchial biopsy | 16.9 | 12.9 | 0.532 |
Brushing | 42.4 | 56.5 | 0.122 |
TBB | 54.2 | 64.5 | 0.250 |
TBNA | 25.4 | 19.4 | 0.423 |
Washing | 15.3 | 29.0 | 0.069 |
Baseline SpO2 a (%), mean ± SD | 97.1 ± 1.0 | 98.0 ± 1.0 | 0.014 |
Minimum SpO2 b (%), median (IQR) | 89 (87–93) | 96 (92–97) | <0.001 |
Maximum O2 flow (L/min), median (IQR) | 2 (2–4) | 2 (2-2) | <0.001 |
Total dose of midazolam (mg), mean ± SD | 3.9 ± 1.0 | 2.3 ± 0.8 | <0.001 |